NDA 219972 · Bayer Healthcare
Hyrnuo
Sevabertinib · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Nov 19, 2025: To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Nov 19, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 3 recruiting
FAERS reports
11
7 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 17, 2026.
HYRNUO is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. HYRNUO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. ( 1 ) This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Mechanism: Sevabertinib is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2). It also exhibits activity against epidermal growth factor receptor (EGFR). In vitro, sevabertinib inhibited the phosphorylation of HER2 and downstream signaling in cancer cells with HER2 alterations and proliferation of cancer cells overexpressing wild-type HER2 or harboring HER2 mutations. In vivo, sevabertinib demonstrated antitumor activity in subcutaneous mouse xenograft models derived from human NSCLC tumors harboring an activating HER2 exon 20 mutation.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 9, 2026 Supplement 1 · Efficacy · priority review OrphanLabelLetter
- Nov 19, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- HYRNUO · SEVABERTINIB 10MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sevabertinib" as an intervention, any sponsor and status, largest first.
BayerBayer (BAYRY)
NCT06452277 · 444 participants (planned) · Start Aug 28, 2024 · Primary completion Oct 28, 2027
Drug: Sevabertinib; Pembrolizumab and 3 more · For: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Sites: Newport Beach, California; San Diego, California; San Francisco, California · 279 sites in all
BayerBayer (BAYRY)
NCT06760819 · 111 participants (planned) · Start Feb 13, 2025 · Primary completion Feb 2, 2029
Drug: BAY2927088 · For: Advanced Solid Tumors; HER2 Mutation
Sites: Birmingham, Alabama; Duarte, California; Fort Myers, Florida · 54 sites in all
- Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the BodyCompleted
BayerBayer (BAYRY)
NCT07753252 · 42 participants · Start Aug 21, 2026 · Primary completion Oct 8, 2026
Drug: Metformin; Sevabertinib (BAY 2927088) · For: Healthy Participants
Sites: Miami, Florida
BayerBayer (BAYRY)
NCT07102095 · 18 participants · Start Jul 24, 2025 · Primary completion Dec 3, 2025
Drug: Sevabertinib · For: Hepatic Insufficiency; Liver Diseases; Pharmacokinetics and 1 more
Sites: Miami, Florida; Orlando, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea5
- disease progression2
- acute kidney injury1
- anaemia1
- csf test abnormal1
- defaecation urgency1
- drug ineffective1
- erythema1
- lung cancer metastatic1
- lung neoplasm malignant1
- metastases to central nervous system1
- oedema1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Le X, Kim TM, Loong HH, et al. · N Engl J Med 2025 · Multicenter Study, Clinical Trial, Phase I
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.